Baird Maintains Outperform on AdaptHealth, Lowers Price Target to $9
Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $10 to $9.
Stocks · News reference
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — American Healthcare REIT, Inc. (AHR)
Filed: 2026-09-18 AccNo: 0001193125-26-395604 Size: 208 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Axsome Therapeutics shares are trading lower after Deutsche Bank lowered its price target on the stock from $280 to $267.
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247